Clinical Trials Logo

Filter by:
NCT ID: NCT05737953 Recruiting - Clinical trials for Pancreatic Neoplasms

Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples

Start date: July 13, 2022
Phase:
Study type: Observational

The goal of this observational study is to test in patients with cystic tumor of pancreas. The main questions it aims to answer are: Screening of molecular diagnostic markers for pancreatic cystic tumors by cfDNA methylation sequencing of pancreatic cystic fluid and proteomic assays to distinguish benign from malignant and mucinous/non-mucinous, correlate with pathological features, and find molecular features associated with the degree of malignancy. Participants will Provide post-operative cyst fluid specimens.

NCT ID: NCT05737940 Recruiting - Heart Failure Clinical Trials

A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

Re-PHIRE
Start date: April 24, 2023
Phase: Phase 2
Study type: Interventional

This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2

NCT ID: NCT05737563 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma Abdominal Stage 0

PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC

Escape
Start date: February 17, 2023
Phase: Phase 3
Study type: Interventional

This trial is a prospective, multicenter, randomized controlled trial. The sample size was 380. Patients with advanced or metastatic esophageal squamous cell carcinoma will be randomized to receive PD1 antibody combined with mXELIRI or mXELIRI regimens in a 1:1 ratio. The stratification factors include PS status (0 vs 1), PFS of first-line treatment (PFS < 3 months versus PFS ≥3 months) . Six cycles of chemotherapy are planned every 3 weeks, for a total of 18 weeks, after which the investigator can decide whether to provide capecitabine with or without PD1 antibody maintenance therapy. Efficacy assessments were performed every 6 weeks before disease progression during treatment. Survival status was followed every 3 months after disease progression.

NCT ID: NCT05737303 Recruiting - Clinical trials for Epithelial Ovarian Carcinoma Stage IV

Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

Start date: February 24, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with solvent-based taxanes as first-line treatment for patients with advanced primary epithelial ovarian cancer (EOC), primary peritoneal carcinoma or fallopian tube carcinoma.

NCT ID: NCT05737264 Recruiting - Clinical trials for Transcatheter Aortic Valve Replacement

TAVR in Adults With Pure Severe Aortic Regurgitation

SENSE-AR
Start date: December 1, 2022
Phase:
Study type: Observational

The study aimed to evaluate the efficacy and safety of transcatheter aortic valve replacement (TAVR) in patients with severe native valve aortic insufficiency. It is a multicentre, observational cohort study. The primary endpoint consisted of a composite of all-cause death, disabling stroke, or rehospitalization for heart failure at 12 months postoperatively. According to previous research results and opinions of expert groups, the sample size was expected to be 76 cases.

NCT ID: NCT05737160 Recruiting - Clinical trials for Myasthenia Gravis, Generalized

Study of Telitacicept in Generalized Myasthenia Gravis

Start date: March 28, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Telitacicept in the treatment of patients with generalized myasthenia gravis.

NCT ID: NCT05737004 Recruiting - Prostate Cancer Clinical Trials

Effects of Prostate Cancer on Brain Function

Start date: April 13, 2023
Phase:
Study type: Observational

To explore whether the patients with prostate cancer have functional changes in specific brain areas and changes in psychological and mental characteristics compared with the patients without prostate cancer.

NCT ID: NCT05736991 Recruiting - Lung Adenocarcinoma Clinical Trials

Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma

Start date: November 1, 2022
Phase:
Study type: Observational

The purpose of this study is to evaluate the performance of a PET/ CT-based deep learning signature for predicting the grade 3 tumors based on the novel grading system in clinical stage stage I lung adenocarcinoma based on a multicenter prospective cohort.

NCT ID: NCT05736978 Recruiting - AML Clinical Trials

Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results

AVS
Start date: March 31, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia based on MRD results on day 14 of the first cycle.

NCT ID: NCT05736965 Recruiting - AML, Adult Clinical Trials

A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

SAV
Start date: February 20, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia.